Literature DB >> 18989635

Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

Dai Maruyama1, Takashi Watanabe2, Yuji Heike1, Kumiko Nagase1, Noriko Takahashi1, Satoshi Yamasaki1, Fusako Waki1, Hiroki Yokoyama1, Sung-Won Kim1, Yukio Kobayashi1, Shin Aizawa3, Kensei Tobinai1.   

Abstract

Bortezomib blocks the activation of nuclear factor-kappaB-mediated pro-inflammatory cytokines, however, systemic inflammatory symptoms following bortezomib administration have been reported, although their mechanisms remain elusive. Serum samples were obtained from five patients, who participated in a phase I/II study of Japanese patients with relapsed or refractory multiple myeloma (MM), and developed cyclic fever following bortezomib administration, to measure cytokine levels. Significant correlations between interleukin (IL)-6 or interferon (IFN)-gamma and the body temperature were observed in two patients each. Furthermore, we found that IL-6 elevation was not observed after the addition of bortezomib to any examined MM cells alone, but was noted in a case of bone marrow stromal cells (BMSCs) of macrophage origin alone or co-cultured with MM cells. Similarly, a marked increase in IFN-gamma levels was induced by adding bortezomib to BMSCs of fibroblast origin. Although this investigation was a preliminary study with a small number of patients, our results suggested that pro-inflammatory cytokines causing bortezomib-associated fever were secreted from BMSCs rather than MM cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18989635     DOI: 10.1007/s12185-008-0194-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Authors:  Robert Z Orlowski; Thomas E Stinchcombe; Beverly S Mitchell; Thomas C Shea; Albert S Baldwin; Stephanie Stahl; Julian Adams; Dixie-Lee Esseltine; Peter J Elliott; Christine S Pien; Roberto Guerciolini; Jessica K Anderson; Natalie D Depcik-Smith; Rita Bhagat; Mary Jo Lehman; Steven C Novick; Owen A O'Connor; Steven L Soignet
Journal:  J Clin Oncol       Date:  2002-11-15       Impact factor: 44.544

2.  Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.

Authors:  Georg Hess; Volker Wagner; Andreas Kreft; Claus Peter Heussel; Christoph Huber
Journal:  Br J Haematol       Date:  2006-09       Impact factor: 6.998

3.  Establishment of a variety of human bone marrow stromal cell lines by the recombinant SV40-adenovirus vector.

Authors:  S Aizawa; M Yaguchi; M Nakano; S Inokuchi; H Handa; K Toyama
Journal:  J Cell Physiol       Date:  1991-08       Impact factor: 6.384

4.  Key inflammatory signaling pathways are regulated by the proteasome.

Authors:  Jing Shen; Julia Reis; David C Morrison; Christopher Papasian; Sreekumar Raghavakaimal; Christopher Kolbert; Asaf A Qureshi; Stefanie N Vogel; Nilofer Qureshi
Journal:  Shock       Date:  2006-05       Impact factor: 3.454

5.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

6.  Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.

Authors:  Sundar Jagannath; Brian G M Durie; Jeffrey Wolf; Elber Camacho; David Irwin; Jose Lutzky; Marti McKinley; Eli Gabayan; Amitabha Mazumder; David Schenkein; John Crowley
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

7.  Hematopoietic supportive function of human bone marrow stromal cell lines established by a recombinant SV40-adenovirus vector.

Authors:  S Aizawa; M Yaguchi; M Nakano; K Toyama; S Inokuchi; T Imai; M Yasuda; R Nabeshima; H Handa
Journal:  Exp Hematol       Date:  1994-06       Impact factor: 3.084

8.  Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese society of hematology and the Japanese society of clinical hematology.

Authors:  Akihiko Gotoh; Kazuma Ohyashiki; Kazuo Oshimi; Noriko Usui; Tomomitsu Hotta; Kazuo Dan; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2006-12       Impact factor: 2.490

9.  Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production.

Authors:  V Costes; M Portier; Z Y Lu; J F Rossi; R Bataille; B Klein
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

10.  A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Authors:  S Jagannath; B Barlogie; J Berenson; D Siegel; D Irwin; P G Richardson; R Niesvizky; R Alexanian; S A Limentani; M Alsina; J Adams; M Kauffman; D-L Esseltine; D P Schenkein; K C Anderson
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

View more
  8 in total

1.  Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation.

Authors:  Sarah J Cullen; Subramaniam Ponnappan; Usha Ponnappan
Journal:  Biochem Pharmacol       Date:  2009-10-14       Impact factor: 5.858

2.  To b(ortezomib) or not to be: the stroma's the thing.

Authors:  Maxwell M Krem; Jun Yan
Journal:  J Pathol       Date:  2016-09-09       Impact factor: 7.996

3.  Bortezomib inhibits the survival and proliferation of bone marrow stromal cells.

Authors:  Ha-Yon Kim; Ji-Young Moon; Haewon Ryu; Yoon-Seok Choi; Ik-Chan Song; Hyo-Jin Lee; Hwan-Jung Yun; Samyong Kim; Deog-Yeon Jo
Journal:  Blood Res       Date:  2015-06-25

4.  Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity.

Authors:  Tomoko Ikeda; Hiroshi Fujii; Masato Nose; Yukiko Kamogawa; Tsuyoshi Shirai; Yuko Shirota; Tomonori Ishii; Hideo Harigae
Journal:  Arthritis Res Ther       Date:  2017-08-11       Impact factor: 5.156

5.  Molecular Insight Into the IRE1α-Mediated Type I Interferon Response Induced by Proteasome Impairment in Myeloid Cells of the Brain.

Authors:  Maja Studencka-Turski; Gonca Çetin; Heike Junker; Frédéric Ebstein; Elke Krüger
Journal:  Front Immunol       Date:  2019-12-18       Impact factor: 7.561

6.  Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients.

Authors:  T Watanabe; M Mitsuhashi; M Sagawa; M Ri; K Suzuki; M Abe; K Ohmachi; Y Nakagawa; S Nakamura; M Chosa; S Iida; M Kizaki
Journal:  Blood Cancer J       Date:  2013-10-04       Impact factor: 11.037

7.  Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.

Authors:  Kazutake Yoshizawa; Harumi Y Mukai; Michiko Miyazawa; Makiko Miyao; Yoshimasa Ogawa; Kazuma Ohyashiki; Takao Katoh; Masahiko Kusumoto; Akihiko Gemma; Fumikazu Sakai; Yukihiko Sugiyama; Kiyohiko Hatake; Yuh Fukuda; Shoji Kudoh
Journal:  Cancer Sci       Date:  2014-01-21       Impact factor: 6.716

8.  Interleukin-32α promotes the proliferation of multiple myeloma cells by inducing production of IL-6 in bone marrow stromal cells.

Authors:  Xuanru Lin; Li Yang; Gang Wang; Fuming Zi; Haimeng Yan; Xing Guo; Jing Chen; Qingxiao Chen; Xi Huang; Yi Li; Enfan Zhang; Wenjun Wu; Yang Yang; Donghua He; Jingsong He; Zhen Cai
Journal:  Oncotarget       Date:  2017-10-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.